Answers are grounded in this paper and cite their sources.
This editorial highlights findings from the Japanese J-COSSA registry showing earlier symptom-guided recognition of ATTR-CM in the tafamidis era, while underscoring persistent geographic disparities and incomplete adherence to guideline-directed diagnostic testing.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Alexander et al. (2026) conducted an editorial in Transthyretin cardiac amyloidosis (ATTR-CM). Tafamidis was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: